Vir Biotechnology (VIR) Assets Average (2019 - 2026)

Vir Biotechnology has disclosed Assets Average across 8 years of filings, most recently posting $1.0 billion for Q1 2026.

• Assets Average for Q1 2026 came in at $1.0 billion, down 25.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 25.06% YoY), and the FY2025 annual result was $1.2 billion, down 27.62% from the prior year.
• Assets Average came in at $1.0 billion for Q1 2026 at Vir Biotechnology, roughly flat from $1.0 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $2.8 billion in Q2 2022 to a low of $1.0 billion in Q4 2025.
• The 5-year median for Assets Average is $1.9 billion (2024), against an average of $1.9 billion.
• Across the five-year window, Assets Average jumped 151.06% in 2022 and sank 32.1% in 2024, its largest moves.
• Vir Biotechnology's Assets Average stood at $2.7 billion in 2022, then decreased by 27.9% to $2.0 billion in 2023, then dropped by 26.91% to $1.4 billion in 2024, then sank by 30.2% to $1.0 billion in 2025, then gained by 0.3% to $1.0 billion in 2026.
• The last three Assets Average figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.